Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 7604

LEAF president Keith Comito explains the story of Lifespan.io — a crowdsourcing platform and community to support biomedical research aimed at extending healthy human lifespan.
▼▼ More info and links below ▼▼

HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
LEAF / Lifespan.io is a 501©(3) nonprofit organization. Everything we’ve done thus far and everything we will do in the future is thanks to your support — please stand with us to fight the diseases of aging and increase healthy human lifespan.

► Support us with monthly donations by becoming a Lifespan Hero: https://www.lifespan.io/hero
► Make a one-time donation and learn about other ways to support us here: http://lifespan.io/support
► Learn more, and help us #CrowdsourceTheCure: https://www.lifespan.io
► Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

THANKS TO THE SUPPORT OF PEOPLE LIKE YOU, WE HAVE:

Continue reading “Crowdsourcing the Cure for Aging | Life Extension Research, Lifespan.IO, and You” | >

Han from WrySci HX gives you a few different reasons why Neuralink is not quite as scary as you may think, especially if you’re not super familiar in the brain machine interface area. Share with a skeptic! More below ↓↓↓

Please consider supporting 🙏

Patreon: https://www.patreon.com/wrysci_hx

OnlyFans: https://onlyfans.com/han_xavier

Continue reading “Why Neuralink Is Not AS Scary As You May Think” | >

Virgin Hyperloop and Bangalore International Airport Limited (BIAL), operator of the Kempegowda International Airport (BLR), have signed a memorandum of understanding to conduct a pre-feasibility study for a proposed hyperloop from the airport to the city centre.

Virgin says its 1,080km/h vacuum-tube travel concept could whisk passengers in pods downtown in 10 minutes.

Signatories were Sultan bin Sulayem, chairman of Virgin Hyperloop and DP World, and Mr. TM Vijay Bhaskar, chief secretary of the Government of Karnataka and chairman of BIAL’s board of directors.

“A hyperloop-connected airport would dramatically improve the delivery of cargo and create an ultra-efficient supply chain,” Sultan bin Sulayem said.

The study on technical, economic and route feasibility is expected to be done in two six-month phases.

Continue reading “Bangalore airport and Virgin to study feasibility of a hyperloop downtown” | >

Psilocybin startup Compass Pathways goes public at more than $1B. Here’s why Wall Street is starting to see the value in psychedelics.

For several years, investors and psychonauts have predicted that psychedelic medicine would become the next billion-dollar industry, with some value estimates as high as $100 billion. They said substances like MDMA or psilocybin mushrooms would follow a similar regulatory path that cannabis took to the mainstream, going from a Schedule 1 narcotic to a legal, regulated, and highly lucrative medicine.

At least some of these predictions have rung true. On September 18th, Compass Pathways Plc., a London-based company developing psilocybin into a prescription drug in assisted psychotherapy, went public, listing on Nasdaq. The company’s stock jumped 71 percent on its first day of trading and is now estimated to be worth $1.3 billion. Compass Pathways declined to comment for this article. Numinus Wellness Inc and Champignon Brands Inc are two other psychedelic companies that have gone public this year.

Continue reading “Psychedelic Gold Rush? Compass Pathways Goes Public at More than

Psilocybin startup Compass Pathways goes public at more than $1B. Here’s why Wall Street is starting to see the value in psychedelics.

For several years, investors and psychonauts have predicted that psychedelic medicine would become the next billion-dollar industry, with some value estimates as high as $100 billion. They said substances like MDMA or psilocybin mushrooms would follow a similar regulatory path that cannabis took to the mainstream, going from a Schedule 1 narcotic to a legal, regulated, and highly lucrative medicine.

At least some of these predictions have rung true. On September 18th, Compass Pathways Plc., a London-based company developing psilocybin into a prescription drug in assisted psychotherapy, went public, listing on Nasdaq. The company’s stock jumped 71 percent on its first day of trading and is now estimated to be worth $1.3 billion. Compass Pathways declined to comment for this article. Numinus Wellness Inc and Champignon Brands Inc are two other psychedelic companies that have gone public this year.B” | >

Three United States DOE national laboratories – SLAC, Fermilab and Jefferson Lab – have partnered to build an advanced particle accelerator that will power the LCLS-II X-ray laser. Thanks to technology developed for nuclear and high-energy physics, the new X-ray laser will produce a nearly continuous wave of electrons and allow scientists to peer more deeply than ever before into the building blocks of life and matter.

Read more | >

Is it a new asteroid mini–moon or a human-made mini-moon? That’s the question about a small object approaching Earth, called 2020 SO. NASA’s Small Body Database predicts the object will captured by Earth’s gravity in October 2020 and temporarily be trapped in orbit.

But a few unusual characteristics of 2020 SO suggest it might not be a small asteroid, like the two previously known temporary mini-moons that have briefly orbited our planet. Instead, this new object might in fact be an old object from Earth—an old second-stage rocket part from the Surveyor 2 lunar lander mission, launched in 1966.

Mini-moons, or TCOs (Temporarily Captured Objects) have probably occurred more over history than we know, but only two have ever been confirmed: 2006 RH120, which hung out in Earth from 2006 to 2007, and the one discovered earlier this year, 2020 CD3, in Earth orbit from 2018 to 2020. Those objects were definitely small space rocks.

Read more | >

Stem cells are a promising experimental treatment for a variety of diseases. Now researchers at the University of Wisconsin-Madison have found that transplanting neurons grown from stem cells into the brains of mice with Parkinson’s disease repaired the damaged brain circuits, improving the animals’ motor skills.

In people afflicted with Parkinson’s, neurons that produce dopamine begin to break down and die. The disease gradually presents as tremors, involuntary movements, and trouble with walking, speaking and other actions. While it currently can’t be cured, studies are suggesting new ways to slow progression and reduce severity of symptoms through new drugs or repurposed old ones, deep brain stimulation or probiotic treatments.

But an emerging and potentially ground-breaking treatment involves stem cells. In several studies, researchers have used stem cells to grow new dopamine-producing neurons, and then transplant them into animals. And now the UW-Madison team’s work has shown that doing so can help restore brain circuits damaged by Parkinson’s.

Read more | >